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Scope: Sulforaphane (SF) is a natural isothiocyanate in broccoli sprouts with cancer chemo-
preventive activity. This study is aimed to use different methods to develop broccoli sprout
preparations to compare their ability to deliver SF to the mice and to evaluate the kinetics and
biodistribution of SF.
Methods and results: The SF-enriched sprout preparation generated by two-step procedure
(quick-steaming followed bymyrosinase treatment) contained the highest level of SF,whichwas
11 and 5 times higher than the freeze-dried fresh broccoli sprouts and the quick-steamed, freeze-
dried broccoli sprouts, respectively. After oral administration of 2.5 mg/g body weight of the
broccoli sprout preparations, SF was quickly absorbed and distributed throughout the tissues.
The SF-rich preparation resulted in the highest exposure, with peak plasma SF concentration of
337 ng/mL, which is 6.0 times and 2.6 times higher compared to the other two preparations. A
whole body physiologically based pharmacokinetic model (developed with ADAPT 5 software)
suggests that distribution of SF is perfusion-limited in all organs.
Conclusion: This study provides a broccoli sprout preparation that can serve as a good source
of SF, and the model can be utilized to guide the dose designed for the use of broccoli sprout
preparation in chemoprevention.
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1 Introduction
Numerous studies continue to support that dietary intake
of cruciferous vegetables, especially broccoli and broccoli
sprouts, may reduce the risk of different types of malig-
nancies [1]. The cancer chemopreventive properties of these
vegetables have been primarily attributed to isothiocyanates
that occur naturally as the glucosinolate precursors in the
plant [1,2]. In particular, sulforaphane (SF), a member of the
isothiocyanate family, has received extensive attention for its
potent chemopreventive activity [3, 4]. SF has been shown to
be not only effective in preventing chemically induced can-
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cers in animal models [4–7], but also inhibit the growth of
established tumors [8,9]. Early research focused on induction
of Phase 2 enzymes and inhibition of Phase 1 enzymes by SF,
which enhances the detoxification of carcinogens [1, 10]. Fol-
lowing studies suggest that SFoffers protection against tumor
development during the “postinitiation” phase by controlling
cell proliferation, differentiation, apoptosis, cell cycle, angio-
genesis, and metastasis [1, 11]. During the past few years, SF
has been shown to target cancer stem cells through direct
or indirect influence on the self-renewal pathways of cancer
stem cells in a number of studies [12–15].
SF is converted from glucoraphanin, the major glucosi-
nolate in broccoli and broccoli sprouts, by myrosinase, a
-thioglucosidase [4]. Broccoli sprouts contain approximately
20 times more glucoraphanin than mature broccoli, which
represents 74% of all glucosinolates in the sprouts [16]. My-
rosinase is physically separated from glucosinolates in the
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intact plant cells. Disruption of the plant during harvesting,
processing, and chewing leads to loss of cellular compart-
mentalization and subsequent mixing of glucoraphanin and
myrosinase to produce SF [17, 18]. Epithiospecifier protein
(ESP), another protein naturally occurring in broccoli and
broccoli sprouts, directs hydrolysis of glucoraphanin toward
SF nitrile [19]. While SF has been shown to possess cancer
chemopreventive properties, SF nitrile has not.
Glucoraphanin is abundant in broccoli and broccoli
sprouts, however, the processing of these vegetables often
results in decreased intake of SF. Cooking procedures that
inactivate plant myrosinase and ESP were shown to signifi-
cantly reduce the bioavailability of SF [20], although the con-
version of glucoraphanin to SF can be also mediated by the
microflora in human gastrointestinal tract [21]. In addition,
SF is relatively thermolabile [22, 23]. It was shown to rapidly
degrade when the temperature was above 60C [23]. Gluco-
raphanin in broccoli sprouts, on the other hand, is relatively
stable to heat. It was suggested that thermal degradation is
unlikely to be a major cause of glucosinolate loss when cook-
ing time is less than 10 min [24]. The loss of glucoraphanin
during cooking is primarily due to the leaching into the cook-
ing water [25].
Therefore, the two main objectives of this study are: (i)
to use different methods to develop three broccoli sprout
preparations and to compare their ability to deliver SF in
vivo; and (ii) to study the pharmacokinetics and for the first
time to build a physiologically based pharmacokinetic (PBPK)
model of SF in mice after oral administration of the broccoli
sprout preparations. This study will provide useful informa-
tion to optimize dose regimen of broccoli sprout preparation
for cancer chemoprevention studies in the mouse and help
make predication for human studies in the future.
2 Materials and methods
2.1 Chemicals
SF and sulforaphane glutathione conjugate (SF-GSH) were
purchased from LKT Laboratories (St. Paul, MN). Glu-
coraphanin was obtained from Cfm Oskar Tropitzsch
(Marktredwitz, Germany). Sinigrin hydrate and myrosi-
nase (thioglucosidase) were from Sigma-Aldrich (St. Louis,
MO). ACN and methanol of HPLC-grade were purchased
from Fisher Scientific (Pittsburgh, PA). Ammonium acetate
(HPLC-grade) and formic acid (spectroscopic grade) were
purchased from Sigma-Aldrich.
2.2 Broccoli sprout preparations
Broccoli sprouts were purchased from a local Whole Foods
Market (Ann Arbor, MI). The procedure of making broc-
coli sprout preparations is described below and illustrated
in Fig. 1. Fresh broccoli sprouts were quick-frozen in liquid
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Figure 1. Development of three broccoli sprout preparations.
nitrogen, and freeze-dried for 48 h. The dried sprouts were
then ground into fine powder with pestle and mortar to get
“fresh preparation” (FR preparation).
To obtain “steamed preparation” (ST preparation), fresh
broccoli sprouts were quick-steamed for 10 min over boiling
water, frozen in liquid nitrogen, freeze-dried for 48 h, and
then ground into fine powder. The length of steaming was
determined based on several studies that had been done to
characterize the thermal stability of myrosinase and ESP in
intact cruciferous vegetables [26, 27]. The activity of broccoli
myrosinase was shown to be reduced by more than 95% after
a 10 min treatment at 70C [27]. The activity of ESP (which
is more heat-labile than myrosinase) in broccoli and broccoli
sprouts was completely eliminated after the vegetables had
been heated at 70C for 5 min or 60C for 10 min [26].
The ST powder (3 g) was incubated with approximately
5 units of myrosinase in water at 37C for 4 h, with occasional
stirring. The mixture was then frozen in liquid nitrogen and
freeze-dried for 3 days to get SM preparation (steamed prepa-
ration followed by myrosinase treatment). The three prepara-
tions were stored at −80C until used.
2.3 Determination of glucoraphanin in broccoli
sprout preparations
The procedure for measurement of glucoraphanin in broc-
coli sprout preparations was modified from previously re-
ported method described by Tian et al. [28]. Briefly, 50 mg
of sprout preparation was sonicated for 30 min at 70C in
1 mL of 70% aqueous methanol (1 mM sinigrin as internal
standard). After cooling in an ice bath, the supernatant of
the extracts was collected by centrifugation at 4000 rpm for
10 min. The extraction procedure was repeated three times
and the supernatants were combined to ensure the recovery.
The 450 L of each extract was transferred to a glass vial and
dried under nitrogen gas. The dried samples were reconsti-
tuted in 500 L water, filtered through 0.2 m nylon filters,
and diluted 1000-fold in ACN (containing 5 mM ammonium
acetate) for analysis.
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All mass spectra were obtained using a 3200 Q-Trap lin-
ear ion trap quadrupole mass spectrometer (Applied Biosys-
tems, Carlsbad, CA) coupled to an Agilent 1200 Series HPLC
system (Agilent Technologies, Santa Clara, CA). HPLC sep-
aration was performed on a Luna 3-m HILIC column
(50 × 2.00 mm, 3 micron; Phenomenex, Torrance, CA). Mo-
bile phase A (ACN/water 50%/40% containing 5 mM ammo-
nium acetate) was first kept at 0% for 2.5 min, then increased
linearly to 50% in 2.5 min, returned to 100% B (ACN con-
taining 5mM ammonium acetate) andmaintained for 5min.
The flow rate was 400 L/min. Negative ion MS/MS was
conducted to detect glucoraphanin. The mass spectrometric
conditions were as follows: source temperature, 700C; cur-
tain gas (CUR), 20 psi; ionspray voltage (IS), 4500 V; desolva-
tion gas temperature (TEM), 700C; ion source gas 1 (GS1),
40 psi; ion source gas 2 (GS2), 60 psi; collision gas (CAD), 6
psi; entrance potential (EP), 5 eV; collision energy (CE), 45 eV.
The transitions 436.10> 96.9 and 358.10> 96.9 were used to
detect glucoraphanin and sinigrin, respectively. A dwell time
of 200 ms was used for each transition. Data acquisition and
quantitation were performed using Analyst software version
1.4.2 (Applied Biosystems).
2.4 Determination of SF in broccoli sprout
preparations
The procedure for measurement of SF in broccoli sprout
preparations was modified from a previously reported
method [29]. Briefly, 50 mg of sprout preparation was ex-
tracted with 1 mL of ethyl acetate (1 mM sinigrin as internal
standard) by vortexing for 1 min and sonicating in ice bath
for 10 min. After centrifugation at 4000 rpm for 10 min, the
organic layer was collected. The extraction procedure was re-
peated three times, the organic phases were combined and
dried under nitrogen gas. The dried samples were reconsti-
tuted in 1 mL of a mixture of mobile phase A (water contain-
ing 5 mM ammonium acetate and 0.1% formic acid) and B
(ACN containing 0.1% ammoniumacetate) (50:50), sonicated
in ice bath for 10 min, filtered through 0.2 m nylon filters,
and diluted 1000-fold for analysis.
HPLC separation was performed on an Agilent ZORBAX
5-m extend-C18 column (50 × 2.1 mm) (Agilent Technolo-
gies). Mobile phase A (water containing 5 mM ammonium
acetate and 0.1% formic acid) was first kept at 95% for 1 min,
then decreased to 10% andmaintained for 2 min, returned to
5% B (ACN containing 0.1% ammonium acetate) and main-
tained for 3 min. The flow rate was 400 L/min. Positive ion
MS/MS was conducted to detect SF. The mass spectromet-
ric conditions were as follows: source temperature, 400C;
curtain gas (CUR), 30 psi; ionspray voltage (IS), 5500 V; de-
solvation gas temperature (TEM), 400C; ion source gas 1
(GS1), 60 psi; ion source gas 2 (GS2), 40 psi; collision gas
(CAD), high; entrance potential (EP), 4 eV; collision energy
(CE), 15 eV. The transition 178 > 114 was used to detect SF,
and a dwell time of 200 ms was used for the transition.
2.5 Collection of animal samples
All the animal experiments were performed under the guide-
lines of the University Committee on Use and Care of Ani-
mals (UCUCA) at University of Michigan. Female CD-1mice
(20–25 g in body weight) were purchased from Charles River
Laboratories (Wilmington,MA), and randomly separated into
groups (three mice per time point for each broccoli sprout
preparation). Broccoli sprout preparations were suspended
in PBS solution on ice, and administered to themice through
oral gavage (2.5 mg/g body weight). Blood samples were col-
lected into heparinized tubes from each mouse by terminal
cardiac puncture at pre dose and 0.5, 1, 2, 4, 6, 8, 12, and
24 h post dose. The plasma fraction was immediately sep-
arated by centrifugation at 2000 × g for 10 min at 4C and
stored at 80C until analysis. Tissue samples, including heart,
liver, kidney, lung, muscle, and mammary fatpad were im-
mediately dissected, weighed, snap-frozen and ground with
mortar and pestle in liquid nitrogen, and then stored at−80C
until analysis.
To collect urine and feces, mice (n= 5/group) were placed
in metabolic cages (Harvard Apparatus, South Natick, MA)
and dosed with broccoli sprout preparations (2.5 mg/g body
wt) via oral gavage. Pooled urine and feces samples were
collected at pre dose and 1, 2, 4, 6, 8, 12, and 24 h post dose,
and stored at −80C until analysis.
2.6 Determination of SF and SF-GSH
in animal samples
Tissue samples and feces were homogenized using a tissue
homogenizer (Tissuemiser Homogenizer, Fisher Scientific,
Pittsburgh, PA). Plasma, tissue homogenate, urine, or feces
homogenate (50 L) was extracted with 400 L methanol
containing 0.5% formic acid (1 mM sinigrin as internal
standard) and vortexed for 4 min, as described previously
[30]. The supernatant was collected after centrifugation at
13 000 rpm for 5 min. The 450 L of supernatant was trans-
ferred to a clean centrifuge tube and dried. The dried sample
was reconstituted in 200 L of mixture of mobile phase A
(water containing 0.1% formic acid and 5 mM ammonium
acetate) and B (ACN containing 0.1% formic acid), mixed for
3 min, and centrifuged at 13 000 rpm for 5 min. The super-
natant was transferred to HPLC vial for analysis. Similarly
to above, an Applied Biosystems 3200 Q-Trap linear ion trap
quadrupole mass spectrometer coupled to an Agilent 1200
Series HPLC system was used for the quantification of SF
and SF-GSH. The transition 485.3 > 179 was used to detect
SF-GSH.
2.7 Kinetic analysis and PBPK modeling
Theplasma concentrationdatawere analyzed bynoncompart-
mental pharmacokinetic model using WinNonlin software
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(Pharsight Corp., Mountain View, CA). The pharmacokinetic
parameters, Cmax (observedmaximumconcentration), Tmax
(time of observed maximum concentration), AUC0-last (area
under the concentration-time curve from time zero to the
last time point), AUC0-∞ (area under the concentration-
time curve from time zero to infinity) were calculated by the
software.
A whole body PBPKmodel was built with blood and tissue
concentration-time data after oral administration of SM broc-
coli sprout preparation (2.5 mg/g body weight) using ADAPT
5 software [31]. In this model, the whole body of the mouse
is composed of seven tissue compartments and one blood
compartment; a “rest-of-body” compartment is incorporated
to represent all the unsampled tissues (depicted in Fig. 4).
The amount of SF entering the blood was calculated with the
bioavailability (F%) published by Lin et al. [32]. For each in-
dividual organ, as the equation shows, change in amount of
drug in the tissue is equal to the difference between rate in
and rate out.
The physiological parameters were either obtained from
literature [33–35] or determined by experiment and listed in
Table 3. The parameters obtained from individual organmod-
els were used as initial estimates for the whole body model.
The initial estimates of partitioning coefficient were deter-
mined by the ratio of the area under concentration curves
(AUC) between tissue and blood. The AUC values were cal-
culated with noncompartmental analysis by WinNonlin soft-
ware (Pharsight Corp.). All equations were solved simultane-
ously with the maximum likelihood estimator in the ADAPT
5 software [31].
2.8 Statistical analysis
Statistical differences were determined using two-tailed Stu-
dent t-test. Data are presented as mean ± SD (n ≥ 3).
3 Results and discussion
3.1 Development of broccoli sprout preparations
Although glucoraphanin is abundant in broccoli and broccoli
sprouts, the processing of broccoli/broccoli sprouts often re-
sults in the loss of SF. This is attributed to several factors—the
presence of ESP in the plant, inactivation of plant myrosinase
by cooking, the loss of glucoraphanin in the cooking water,
and the low stability of SF at high temperature. ESP directs
Table 1. Glucoraphanin and SF content in three broccoli sprout
preparations. Data are presented as mean ± SD (n = 3)
Broccoli sprout Glucoraphanin SF (mg/g
preparations (mg/g dry wt.) dry wt.)
Steamed + myrosinase (SM) 0.09 ± 0.01 4.25 ± 0.15
Steamed (ST) 22.74 ± 1.33 0.92 ± 0.05
Fresh (FR) 1.94 ± 0.10 0.39 ± 0.04
hydrolysis of glucoraphanin toward SF nitrile, which does not
have cancer chemopreventive properties [19]. However, cook-
ing processes that inactivate plant ESP and myrosinase sig-
nificantly reduce the bioavailability of SF up to threefold [20],
indicating the incomplete conversion of glucoraphanin to SF
by microflora in human gastrointestinal tract. In addition,
glucoraphanin is easily leached into the cooking water during
preparation [25]. Thus, steam cooking hasminimal effects on
glucosinolates of broccoli florets compared to high-pressure
boiling, conventional boiling, and microwave cooking [25].
Furthermore, SF once formed is relatively unstable at high
temperature [22, 23].
Therefore, we developed three different broccoli sprout
preparations and measured the content of SF and gluco-
raphanin in these preparations, as described in Section Ma-
terials and methods and illustrated in Fig. 1. They are freeze-
dried fresh broccoli sprouts (FR preparation), quick-steamed,
freeze-dried broccoli sprouts (ST preparation), and a SF-
enriched SM preparation. We used a two-step method to
generate the SM preparation. First, we quick-steamed broc-
coli sprouts to inactive myrosinase and ESP in the plant and
thus minimize the hydrolysis of glucoraphanin. The length
of steamingwas determined based on several studies that had
been done to characterize the thermal stability of myrosinase
and ESP in intact cruciferous vegetables [26, 27]. Then, we
converted glucoraphanin to SF by adding back myrosinase.
This product was then freeze-dried immediately to preserve
the high level of SF.
The retention of SF and glucoraphanin in the broccoli
sprout preparations was largely affected by the way the prepa-
ration was made (Table 1). ST preparation preserved the
highest level of glucoraphanin, while SM preparation con-
tained the largest amount of SF among all the three prepara-
tions. The glucoraphanin content of ST preparation (22.74 ±
1.33mg/g dry wt.) was approximately 12- and 253-fold higher
than that of FR (1.94 ± 0.10 mg/g dry wt.) and SM (0.09 ±
0.01 mg/g dry wt.), respectively. As expected, the gluco-
raphanin in SM preparation was converted to SF by incu-
bation with myrosinase. The SF content of SM was 4.25 ±
0.15 mg/g dry wt., which is approximately 11 and 5 times
higher than FR (0.39 ± 0.04 mg/g dry wt.) and ST (0.92 ±
0.05 mg/g dry wt.), respectively. Low content of both SF and
glucoraphanin inFRpreparation suggests that glucoraphanin
might be converted to SF nitrile during the processing and
storage. The low stability of SF might also contribute to this
observation.
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Figure 2. Plasma concentration profiles of SF (A), SF-GSH (B) after a single oral administration of 2.5 mg/g body weight of three different
broccoli sprout preparations in mice (mean ± SD, n = 3). Blood samples were collected from each mouse by terminal cardiac puncture at
pre dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 h post dose, and the plasma fraction was immediately separated. The concentrations of SF and
SF-GSH were determined by LC-MS/MS.
3.2 Kinetic study of SF and SF-GSH after oral
administration of the broccoli sprout
preparations in mice
Next, we evaluated these broccoli sprout preparations for their
ability to deliver SF in mouse plasma after oral administra-
tion and examined the in vivo pharmacokinetics and tissue
distribution of SF. Each preparation was administered into
CD-1 mice by oral gavage, and the plasma and tissue samples
were collected at 0, 0.5, 1, 2, 4, 8, 12, 24 h. Previous studies
have shown that after absorption SF is quickly conjugated to
glutathione to form SF-GSH conjugates, which are the major
means of transport of SF throughout the body [36], therefore,
we also measured SF-GSH in plasma.
The plasma concentration-time profiles of SF andSF-GSH
are shown in Fig. 2. Oral administration of all three prepa-
rations led to an immediate increase in the levels of SF and
SF-GSH in plasma, indicating a rapid oral absorption of SF.
SF was shown to efficiently and rapidly absorbed in human
subjects given a single dose of broccoli extract, with peak
plasma concentration occurring 1 h after feeding and a half
life of 1.77 ± 0.13 h [1, 37, 38]. Similarly, in our study, fol-
lowing oral administration of broccoli sprout preparations,
the greatest plasma concentration we measured occurred at
0.5 h.
Notably, we observed a “secondary peak” at the time point
of 2 h after oral administration of ST preparation, suggesting
that it took approximately 2 h for the conversion of gluco-
raphanin to SF by gut microflora. Lai et al. reported that
introduction of glucoraphanin (150 mol/kg body weight)
directly into the cecum resulted in a significant rise of isothio-
cyanates (free SF plus glutathione metabolites) in the mesen-
teric plasmaby 120min [39]. Our observation of the secondary
peak at 2 h is consistent with this finding [39].
A summary of pharmacokinetic parameters is listed in
Table 2. The highest plasma concentration of SF was 6.0 and
2.6 times higher when SM preparation (337 ng/mL) was ad-
ministered, compared to FR (56 ng/mL) and ST (130 ng/mL)
preparations, respectively. The AUC0-last of SM preparation
(856 ng × h/mL) was 8.1 and 2.1 times higher, compared
to FR (106 ng × h/mL) and ST (399 ng × h/mL) prepara-
tions, respectively. Similarly, the AUC0-∞ in mice after oral
administration of SM preparation (864 ng × h/mL) was 7.6
and 2.1 times higher, compared to FR (113 ng × h/mL) and
ST (402 ng × h/mL) preparations, respectively. The AUC
value reflects the overall exposure. Likewise, for SF-GSH
Table 2. Pharmacokinetic parameters of SF and SF-GSH after a single oral administration of 2.5 mg/g body weight of broccoli sprout
preparations in mice
Broccoli sprout preparations SF SF-GSH
SM ST FR SM ST FR
AUC0-∞ (ng × h/mL) 864 402 113 2290 867 193
AUC0-last (ng × h/mL) 856 399 106 2290 866 191
Tmax (h) 0.5 0.5 0.5 0.5 0.5 0.5
Cmax (ng/mL) 337 130 56 1090 272 132
T1/2 (h) 4.35 3.82 6.9 2.81 2.85 4.54
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conjugate, the Cmax of SM group (1090 ng/mL) was 8.3 and
4.0 times higher than the Cmax of FR (132 ng/mL) and ST
(272 ng/mL) groups. The AUC in mice after oral admin-
istration of SM preparation (AUC0-last: 2290 ng × h/mL;
AUC0-∞: 2290 ng× h/mL) was 11.9 and 2.6 times higher, in
comparison to FR (AUC0-last: 191 ng × h/mL; AUC0-∞:
193 ng × h/mL) and ST (AUC0-last: 866 ng × h/mL;
AUC0-∞: 867 ng × h/mL) preparations, respectively. Col-
lectively, these data demonstrate that SM preparation can
deliver the highest amount of SF and SF-GSH into plasma.
3.3 Physiologically based pharmacokinetic modeling
Given that the plasma levels of SF and SF-GSHwere very low
for FR preparation, we only evaluated tissue distribution for
ST and SM groups. As shown in Fig. 3, levels of SF in liver,
kidney, lung, heart, muscle, and mammary fatpad tissues
were highest at 0.5 h after administration of SM prepara-
tion, reaching 449.97 ± 90.45, 235.26 ± 33.84, 90.49 ± 14.34,
58.55 ± 10.73, 34.90 ± 11.47, and 19.40 ± 6.41 ng/g tissue,
respectively, and decreased thereafter. Similarly, the greatest
tissue concentrations of SF-GSH we measured occurred at
0.5 h (1857.97 ± 288.10, 51.85 ± 5.08, 536.30 ± 118.33,
190.76± 63.30, and 61.33± 2.16 ng/g tissue for liver, kidney,
lung, heart, and muscle, respectively). SF-GSH was under
LOD inmammary fatpad.Our data have shown that tissue lev-
els of SF reached the highest at 0.5 h after dosing, indicating
that SF was quickly distributed throughout the mouse body
after consumption of broccoli sprout preparations, which is
in agreement with previous studies [37].
A PBPK model was developed to describe the
concentration-time profiles in different tissues. PBPK mod-
els aremathematicalmodels derived from the anatomical and
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Figure 3. Tissue concentration profiles of SF and SF-GSH after a single oral administration of 2.5 mg/g body weight of SM (A & B) and ST
(C & D) preparations in mice (mean ± SD, n = 3). Tissue samples, including heart, liver, kidney, lung, muscle, and mammary fatpad were
collected at pre dose and 0.5, 1, 2, 4, 6, 8, 12, and 24 h post dose. The concentrations of SF and SF-GSH were determined by LC-MS/MS.
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Figure 4. Whole body PBPK model for suforaphane following an
oral dose. Thewhole body of themouse is composed of seven tis-
sue compartments and one blood compartment; a “rest-of-body”
compartment is incorporated to represent all the unsampled
tissues.
physiological structure of the organism studied [40]. They are
used to characterize the pharmacokinetics of drugswithin the
body in relation to blood flows, tissue volumes, routes of ad-
ministration, and other factors. PBPKmodeling offers several
advantages. It helps to gain insight of the pharmacokinetic be-
havior of the compound, in animals, in different organs that
could otherwise never be assessed in humans [40, 41]. The
whole body PBPK model was constructed as shown in Fig. 4
to describe the SF disposition in plasma, lung, heart, kid-
ney, muscle, fatpad, and liver. Physiological parameters used
in the model are reported in Table 3. They were either ob-
tained from literature [33–35] or determined by experiment.
The model simulated plasma and tissue concentration–time
Table 3. Physiological parameters used in the whole body model
in mice
Total Volume Organ blood flow
(mL) (% cardiac output)
Whole body 23.31a) —
Blood 1.230b) 100
Lung 0.19a) 100
Liver 1.29a) 16.1b)
Fatpad 0.21a) 0.11c)
Heart 0.13a) 6.6b)
Kidney 0.35a) 9.1b)
Muscle 9.638b) 15.9b)
Rest of the body 10.272a) 52.2
a) Determined by averaging the experimental data for each organ
and assuming a density of 1 g/mL except for bone (1.5 g/mL);
average body weight = 25.1 g.
b) Values obtained from Brown et al. [42].
c) Values obtained from Wang et al. [43], cardiac output = 51.36
mL/min/100 g body weight.
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Figure 5. Plasma and tissue concentration time profiles of SF
following a single oral dose of 2.5 mg/g body weight of SM broc-
coli sprout preparations in mice. Data points represent observed
concentrations (mean ± SD, n = 3) and lines are PBPK model-
simulated profiles.
profiles of SF following a single dose of 2.5 mg/g body weight
of SM broccoli sprout preparation in CD-1 mice were shown
in Fig. 5 (lines). The model depicted the observed data rela-
tively well for all the organs studied. A perfusion rate-limited
tissue model was adequate to describe the pharmacokinetics
of SF for all the sampled organs, indicating that on entry
with the blood circulation, the drug distributed freely and
instantly across the membrane without diffusion barriers.
After oral administration, SF was quickly absorbed and the
estimated first-order absorption rate constant was 0.32 h−1.
To the best knowledge of the authors, this is the first study
to provide comprehensive pharmacokinetic data and build a
PBPK model to describe the disposition of SF from broccoli
sprouts preparation. This mouse model can be used to de-
sign dose regimen for efficacy study in mice and could be
very helpful to determine efficacious dose in human after
extrapolation.
4 Concluding remarks
In conclusion, as we hypothesized, the SF-rich broccoli
sprout preparation (SM) generated by the two-step proce-
dure contained the highest level of SF and produced the
highest plasma concentration of SF. The freeze-dried broc-
coli sprouts with plant enzyme activities (FR) resulted in the
lowest plasma concentration. The pharmacokinetic analysis
and biodistribution indicate that SF was well and rapidly ab-
sorbed and distributed to various tissues following oral ad-
ministration of our broccoli sprout preparations in the mice.
The PBPK model for SF can be utilized to guide the dose
regimen design for cancer chemoprevention efficacy studies
in mice and could be very helpful to determine efficacious
dose in humans after extrapolation.
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